Vaccines reorg?

[anonymous]

Not deserving? I’m sure every grade level has examples of this. How is this possible move going to inspire and engage the team?

Turn that frown upside down.
No more roast beef.
Long Live Thigh Meat

 

[anonymous]

It's happened before in the U.S. when a new division or unit is created and those in existing 6 roles were changed to 7.
What's your option? Contact your union rep?

 

[anonymous]

Conference calls that talk in circles with nothing really being said. Typical GSK.

 

[anonymous]

So what is going on with the re-org?

 

[anonymous]

So what is going on with the re-org?

Great question. Nobody knows. They are going to “figure it out” as they go! Ha.

 

[anonymous]

Lot’s of talking in circles by leadership on these national calls without saying anything.

 

[anonymous]

bringing air to vaccines was a mistake. once market saturation is achieved, no need for those losers anymore. they are just sample dropping caterers. the reps who contract are the only ones pulling their weight in this situation.

 

[anonymous]

bringing air to vaccines was a mistake. once market saturation is achieved, no need for those losers anymore. they are just sample dropping caterers. the reps who contract are the only ones pulling their weight in this situation.

Contract people? Syneos? Yeah, all the winners want to work for Syneos. That’s why they get paid the big bucks

 

[anonymous]

Hey! At least we will be walking "hand in hand" with Joaquin down this road! I couldn't understand either one of those dolts on the Ecosystem Reorg call.

 

[anonymous]

GSK stock not doing so well.

 

[anonymous]

GSK stock not doing so well.

Curious if there will be any displacement this time around.

 

[anonymous]

GSK stock not doing so well.

It seems to me they should have sacked the CEO after so many years of underperformance.

 

[anonymous]

It seems to me they should have sacked the CEO after so many years of underperformance.

The issue isn't that the CEO is underperforming. It's that we are under-appreciating the CEO's performance.

 

[anonymous]

Nobody knows anything about what’s going on in this division. At least that’s what management has been saying. I’m sure this meeting in Atlanta will have everyone coming home with more questions than answers.

 

[anonymous]

The issue isn't that the CEO is underperforming. It's that we are under-appreciating the CEO's performance.

Methinks she will get the sack.

 

[anonymous]

Emma recently stated that as we move forward at GSK, let's focus on incremental progress rather than groundbreaking discoveries. Our aim is not to revolutionize healthcare, but to cautiously tread the path of marginal improvement. Let's prioritize profit margins over patient outcomes and ensure that our products meet the bare minimum of regulatory standards. Remember, it's not about changing lives; it's about maintaining a steady revenue stream.

 

[anonymous]

Emma recently stated that as we move forward at GSK, let's focus on incremental progress rather than groundbreaking discoveries. Our aim is not to revolutionize healthcare, but to cautiously tread the path of marginal improvement. Let's prioritize profit margins over patient outcomes and ensure that our products meet the bare minimum of regulatory standards. Remember, it's not about changing lives; it's about maintaining a steady revenue stream.

Absolutely. Spot on.

 

[anonymous]

Emma recently stated that as we move forward at GSK, let's focus on incremental progress rather than groundbreaking discoveries. Our aim is not to revolutionize healthcare, but to cautiously tread the path of marginal improvement. Let's prioritize profit margins over patient outcomes and ensure that our products meet the bare minimum of regulatory standards. Remember, it's not about changing lives; it's about maintaining a steady revenue stream.

Intended or not, this is Gsk 25 years ago till today. Uninspiring.

 

[anonymous]

Methinks she will get the sack.

 

[anonymous]

Methinks she will get the sack.

Geek